Comparison of renal response to four different induction therapies in Japanese patients with lupus nephritis class III or IV: A single-centre retrospective study

Hironari Hanaoka, Tomofumi Kiyokawa, Harunobu Iida, Kana Ishimori, Yukiko Takakuwa, Takahiro Okazaki, Hidehiro Yamada, Daisuke Ichikawa, Sayuri Shirai, Junki Koike, Shoichi Ozaki

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The recent recommendations for the management of lupus nephritis suggest that racial background should be considered while choosing induction therapy. However, the responses to different induction regimens have been poorly studied in Japanese population. Here, we assessed the renal response to different induction therapies in Japanese patients with lupus nephritis class III or IV. The records of 64 patients with biopsy-proven lupus nephritis class III or IV were retrospectively evaluated according to therapy received: monthly intravenous cyclophosphamide (IVCY), the Euro-lupus nephritis trial (ELNT) protocol-IVCY, tacrolimus (TAC), or mycophenolate mofetil (MMF). We investigated cumulative complete renal response (CR) rates and relapse rates for each group for 3 years. Organ damage was assessed with the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). There were 22 patients on monthly IVCY, 18 on ELNT-IVCY, 13 on TAC, and 11 on MMF. Lower systemic lupus erythematosus disease activity index (SLEDAI) and higher CH50 were found in the TAC group at baseline (p<0.01 and p<0.01, respectively). There were no significant differences of cumulative CR rates and relapse free survival for 3 years among the four different therapeutic regimens (p = 0.2 and p = 0.2, respectively). There was a tendency to have early response and early relapse in TAC group and late response in MMF group. The SDI increase over 3 years was found more frequently in the TAC group than in the monthly-IVCY group (p = 0.04). Multivariate analysis indicated that CR at 3 months was independent prognosticator for low damage accrual. Regarding lower damage accrual, early CR achievement might be essential in induction therapy regardless of immunosuppressant choice.

Original languageEnglish
Article numbere0175152
JournalPloS one
Volume12
Issue number4
DOIs
Publication statusPublished - 2017 Apr 1
Externally publishedYes

Fingerprint

tacrolimus
nephritis
Lupus Nephritis
cyclophosphamide
Tacrolimus
retrospective studies
Cyclophosphamide
Mycophenolic Acid
Retrospective Studies
kidneys
Kidney
relapse
therapeutics
Recurrence
Therapeutics
immunosuppressive agents
lupus erythematosus
Biopsy
Immunosuppressive Agents
Clinical Protocols

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Comparison of renal response to four different induction therapies in Japanese patients with lupus nephritis class III or IV : A single-centre retrospective study. / Hanaoka, Hironari; Kiyokawa, Tomofumi; Iida, Harunobu; Ishimori, Kana; Takakuwa, Yukiko; Okazaki, Takahiro; Yamada, Hidehiro; Ichikawa, Daisuke; Shirai, Sayuri; Koike, Junki; Ozaki, Shoichi.

In: PloS one, Vol. 12, No. 4, e0175152, 01.04.2017.

Research output: Contribution to journalArticle

Hanaoka, H, Kiyokawa, T, Iida, H, Ishimori, K, Takakuwa, Y, Okazaki, T, Yamada, H, Ichikawa, D, Shirai, S, Koike, J & Ozaki, S 2017, 'Comparison of renal response to four different induction therapies in Japanese patients with lupus nephritis class III or IV: A single-centre retrospective study', PloS one, vol. 12, no. 4, e0175152. https://doi.org/10.1371/journal.pone.0175152
Hanaoka, Hironari ; Kiyokawa, Tomofumi ; Iida, Harunobu ; Ishimori, Kana ; Takakuwa, Yukiko ; Okazaki, Takahiro ; Yamada, Hidehiro ; Ichikawa, Daisuke ; Shirai, Sayuri ; Koike, Junki ; Ozaki, Shoichi. / Comparison of renal response to four different induction therapies in Japanese patients with lupus nephritis class III or IV : A single-centre retrospective study. In: PloS one. 2017 ; Vol. 12, No. 4.
@article{d5b2866f833a4c3aa4c7b0e23924034e,
title = "Comparison of renal response to four different induction therapies in Japanese patients with lupus nephritis class III or IV: A single-centre retrospective study",
abstract = "The recent recommendations for the management of lupus nephritis suggest that racial background should be considered while choosing induction therapy. However, the responses to different induction regimens have been poorly studied in Japanese population. Here, we assessed the renal response to different induction therapies in Japanese patients with lupus nephritis class III or IV. The records of 64 patients with biopsy-proven lupus nephritis class III or IV were retrospectively evaluated according to therapy received: monthly intravenous cyclophosphamide (IVCY), the Euro-lupus nephritis trial (ELNT) protocol-IVCY, tacrolimus (TAC), or mycophenolate mofetil (MMF). We investigated cumulative complete renal response (CR) rates and relapse rates for each group for 3 years. Organ damage was assessed with the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). There were 22 patients on monthly IVCY, 18 on ELNT-IVCY, 13 on TAC, and 11 on MMF. Lower systemic lupus erythematosus disease activity index (SLEDAI) and higher CH50 were found in the TAC group at baseline (p<0.01 and p<0.01, respectively). There were no significant differences of cumulative CR rates and relapse free survival for 3 years among the four different therapeutic regimens (p = 0.2 and p = 0.2, respectively). There was a tendency to have early response and early relapse in TAC group and late response in MMF group. The SDI increase over 3 years was found more frequently in the TAC group than in the monthly-IVCY group (p = 0.04). Multivariate analysis indicated that CR at 3 months was independent prognosticator for low damage accrual. Regarding lower damage accrual, early CR achievement might be essential in induction therapy regardless of immunosuppressant choice.",
author = "Hironari Hanaoka and Tomofumi Kiyokawa and Harunobu Iida and Kana Ishimori and Yukiko Takakuwa and Takahiro Okazaki and Hidehiro Yamada and Daisuke Ichikawa and Sayuri Shirai and Junki Koike and Shoichi Ozaki",
year = "2017",
month = "4",
day = "1",
doi = "10.1371/journal.pone.0175152",
language = "English",
volume = "12",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

TY - JOUR

T1 - Comparison of renal response to four different induction therapies in Japanese patients with lupus nephritis class III or IV

T2 - A single-centre retrospective study

AU - Hanaoka, Hironari

AU - Kiyokawa, Tomofumi

AU - Iida, Harunobu

AU - Ishimori, Kana

AU - Takakuwa, Yukiko

AU - Okazaki, Takahiro

AU - Yamada, Hidehiro

AU - Ichikawa, Daisuke

AU - Shirai, Sayuri

AU - Koike, Junki

AU - Ozaki, Shoichi

PY - 2017/4/1

Y1 - 2017/4/1

N2 - The recent recommendations for the management of lupus nephritis suggest that racial background should be considered while choosing induction therapy. However, the responses to different induction regimens have been poorly studied in Japanese population. Here, we assessed the renal response to different induction therapies in Japanese patients with lupus nephritis class III or IV. The records of 64 patients with biopsy-proven lupus nephritis class III or IV were retrospectively evaluated according to therapy received: monthly intravenous cyclophosphamide (IVCY), the Euro-lupus nephritis trial (ELNT) protocol-IVCY, tacrolimus (TAC), or mycophenolate mofetil (MMF). We investigated cumulative complete renal response (CR) rates and relapse rates for each group for 3 years. Organ damage was assessed with the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). There were 22 patients on monthly IVCY, 18 on ELNT-IVCY, 13 on TAC, and 11 on MMF. Lower systemic lupus erythematosus disease activity index (SLEDAI) and higher CH50 were found in the TAC group at baseline (p<0.01 and p<0.01, respectively). There were no significant differences of cumulative CR rates and relapse free survival for 3 years among the four different therapeutic regimens (p = 0.2 and p = 0.2, respectively). There was a tendency to have early response and early relapse in TAC group and late response in MMF group. The SDI increase over 3 years was found more frequently in the TAC group than in the monthly-IVCY group (p = 0.04). Multivariate analysis indicated that CR at 3 months was independent prognosticator for low damage accrual. Regarding lower damage accrual, early CR achievement might be essential in induction therapy regardless of immunosuppressant choice.

AB - The recent recommendations for the management of lupus nephritis suggest that racial background should be considered while choosing induction therapy. However, the responses to different induction regimens have been poorly studied in Japanese population. Here, we assessed the renal response to different induction therapies in Japanese patients with lupus nephritis class III or IV. The records of 64 patients with biopsy-proven lupus nephritis class III or IV were retrospectively evaluated according to therapy received: monthly intravenous cyclophosphamide (IVCY), the Euro-lupus nephritis trial (ELNT) protocol-IVCY, tacrolimus (TAC), or mycophenolate mofetil (MMF). We investigated cumulative complete renal response (CR) rates and relapse rates for each group for 3 years. Organ damage was assessed with the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). There were 22 patients on monthly IVCY, 18 on ELNT-IVCY, 13 on TAC, and 11 on MMF. Lower systemic lupus erythematosus disease activity index (SLEDAI) and higher CH50 were found in the TAC group at baseline (p<0.01 and p<0.01, respectively). There were no significant differences of cumulative CR rates and relapse free survival for 3 years among the four different therapeutic regimens (p = 0.2 and p = 0.2, respectively). There was a tendency to have early response and early relapse in TAC group and late response in MMF group. The SDI increase over 3 years was found more frequently in the TAC group than in the monthly-IVCY group (p = 0.04). Multivariate analysis indicated that CR at 3 months was independent prognosticator for low damage accrual. Regarding lower damage accrual, early CR achievement might be essential in induction therapy regardless of immunosuppressant choice.

UR - http://www.scopus.com/inward/record.url?scp=85017145300&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017145300&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0175152

DO - 10.1371/journal.pone.0175152

M3 - Article

C2 - 28384208

AN - SCOPUS:85017145300

VL - 12

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 4

M1 - e0175152

ER -